KORU Medical Systems (Nasdaq:KRMD) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

KRMD Overzicht aandelen

KORU Medical Systems, Inc. ontwikkelt en produceert medische hulpmiddelen en benodigdheden in de Verenigde Staten en internationaal.

Over het bedrijf

KRMD fundamentele analyse
Sneeuwvlok Score
Waardering	1/6
Toekomstige groei	1/6
Prestaties in het verleden	0/6
Financiële gezondheid	6/6
Dividenden	0/6

Beloningen

De omzet zal naar verwachting met 15.23% per jaar groeien

Analisten zijn het erover eens dat de aandelenkoers met 33.3% zal stijgen

Risicoanalyse

Momenteel verlieslatend en er wordt niet verwacht dat dit de komende 3 jaar winstgevend zal worden.

KORU Medical Systems, Inc. Concurrenten

Myomo

NYSEAM:MYO

US$119.4m

EDAP TMS

NasdaqGM:EDAP

US$97.6m

Kewaunee Scientific

NasdaqGM:KEQU

US$91.2m

Semler Scientific

NasdaqCM:SMLR

US$168.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor KORU Medical Systems
Historische aandelenkoersen
Huidige aandelenkoers	US$2.69
52 Week Hoogtepunt	US$3.09
52 Week Laag	US$1.98
Bèta	0.42
11 maand verandering	10.25%
3 maanden verandering	6.75%
1 Jaar Verandering	2.28%
33 jaar verandering	-2.18%
5 jaar verandering	-22.48%
Verandering sinds IPO	6,625.00%

Recent nieuws en updates

We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To Grow

Aug 29

KORU Medical Systems, Inc. (NASDAQ:KRMD) Doing What It Can To Lift Shares

Jul 30

Recent updates

We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To Grow

Aug 29

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% Lower

Jul 14

We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate

Sep 27

Repro Med Systems (NASDAQ:KRMD) Is In A Good Position To Deliver On Growth Plans

Oct 27

Analysts Have Been Trimming Their Repro Med Systems, Inc. (NASDAQ:KRMD) Price Target After Its Latest Report

Aug 14

Is Repro Med Systems, Inc.'s (NASDAQ:KRMD) Shareholder Ownership Skewed Towards Insiders?

Feb 22

Returns On Capital At Repro Med Systems (NASDAQ:KRMD) Paint An Interesting Picture

Jan 27

KORU Medical Systems: A Razor & Razor Blade Story

Jan 11

Is Repro Med Systems, Inc. (NASDAQ:KRMD) Trading At A 50% Discount?

Dec 29

Have Insiders Been Buying Repro Med Systems, Inc. (NASDAQ:KRMD) Shares This Year?

Dec 03

Rendement voor aandeelhouders

	KRMD	US Medical Equipment	US Markt
7D	-0.4%	-2.5%	-0.7%
1Y	2.3%	19.8%	32.5%

Rendement versus industrie: KRMD presteerde slechter dan de US Medical Equipment -sector, die het afgelopen jaar een rendement van 22.3 % opleverde.

Rendement versus markt: KRMD presteerde slechter dan US Market, dat het afgelopen jaar een rendement van 33.4 % opleverde.

Prijsvolatiliteit

Is KRMD's price volatile compared to industry and market?
KRMD volatility
KRMD Average Weekly Movement	7.8%
Medical Equipment Industry Average Movement	8.5%
Market Average Movement	6.4%
10% most volatile stocks in US Market	14.9%
10% least volatile stocks in US Market	3.2%

Stabiele aandelenkoers: KRMD heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 9% ) van KRMD is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1980	82	Linda Tharby	www.korumedical.com

KORU Medical Systems, Inc. ontwikkelt en produceert medische hulpmiddelen en benodigdheden in de Verenigde Staten en daarbuiten. Het bedrijf biedt de Freedom-infuussystemen om levensreddende therapieën toe te dienen aan patiënten met chronische ziekten, zoals primaire immunodeficiëntieziekten, chronische inflammatoire demyeliniserende polyneuropathie en paroxismale nachtelijke hemoglobinurie. De producten van het bedrijf omvatten het FREEDOM60 infusiesysteem, de FreedomEdge injectiespuitdriver, HIgH-Flo subcutane veiligheidsnaalden en producten met precisiestroomslang.

KORU Medical Systems, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van KORU Medical Systems zich tot de beurswaarde?
KRMD fundamentele statistieken
Marktkapitalisatie	US$121.52m
Inkomsten(TTM)	-US$11.76m
Inkomsten(TTM)	US$30.82m

4.0x

P/S-verhouding

-10.5x

Koers/Winstverhouding

Is KRMD overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
KRMD resultatenrekening (TTM)
Inkomsten	US$30.82m
Kosten van inkomsten	US$11.56m
Brutowinst	US$19.26m
Overige uitgaven	US$31.02m
Inkomsten	-US$11.76m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.26
Brutomarge	62.49%
Nettowinstmarge	-38.16%
Schuld/Eigen Vermogen Verhouding	0%

Hoe presteerde KRMD op de lange termijn?

Bekijk historische prestaties en vergelijking

KRMD Overzicht aandelen

Beloningen

Risicoanalyse

KORU Medical Systems, Inc. Concurrenten

NYSEAM:MYO

US$119.4m

NasdaqGM:EDAP

US$97.6m

NasdaqGM:KEQU

US$91.2m

NasdaqCM:SMLR

US$168.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To Grow

Consensus estimates of losses per share improve by 20%

New minor risk - Market cap size

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

KORU Medical Systems, Inc. Revises Revenue Guidance for the Full Year 2024

KORU Medical Systems, Inc. (NASDAQ:KRMD) Doing What It Can To Lift Shares

Recent updates

We're Interested To See How KORU Medical Systems (NASDAQ:KRMD) Uses Its Cash Hoard To Grow

Consensus estimates of losses per share improve by 20%

New minor risk - Market cap size

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

KORU Medical Systems, Inc. Revises Revenue Guidance for the Full Year 2024

KORU Medical Systems, Inc. (NASDAQ:KRMD) Doing What It Can To Lift Shares

KORU Medical Systems, Inc Announces Executive Changes

KORU Medical Systems, Inc. to Report Q2, 2024 Results on Aug 07, 2024

KORU Medical Systems, Inc.(NasdaqCM:KRMD) dropped from Russell Small Cap Comp Growth Index

KORU Medical Systems Receives Regulatory Clearance for FreedomEdge Infusion System in Japan

KORU Medical Systems, Inc. Announces Collaboration with Global Pharmaceutical Company to Initiate Feasibility Study with Its Freedom Infusion System for FDA and EMA Approved Subcutaneous Oncology Biologic Drug

Consensus EPS estimates fall by 15%

KORU Medical Systems, Inc. reaffirms Financial Guidance for the Full Year of 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

KORU Medical Systems, Inc. Reaffirmes Financial Guidance for the Full Year of 2024

KORU Medical Systems, Inc. to Report Q1, 2024 Results on May 01, 2024

KORU Medical Systems, Inc., Annual General Meeting, May 09, 2024

Full year 2023 earnings: EPS misses analyst expectations

KORU Medical Systems, Inc. Provides Earnings Guidance for the Full Year 2024

KORU Medical Systems, Inc. Announces A Feasibility Study to Enter Ambulatory Infusion Settings with A Commercialized Biologic

KORU Medical Systems, Inc. to Report Q4, 2023 Results on Mar 13, 2024

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Revenues

Consensus EPS estimates upgraded to US$0.18 loss, revenue downgraded

Koru Medical Systems, Inc. Appoints Kenneth Miller as Chief Commercial Officer

New minor risk - Market cap size

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

KORU Medical Systems, Inc. Receives FDA 510(k) Clearance for FREEDOM60 Infusion System With Hizentra 50 ML Prefilled Syringes

KORU Medical Systems, Inc. to Report Q3, 2023 Results on Nov 08, 2023

High number of new directors

We're Hopeful That KORU Medical Systems (NASDAQ:KRMD) Will Use Its Cash Wisely

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

KORU Medical Systems, Inc. Updates Revenue Guidance for the Full Year 2023

Price target decreased by 10% to US$4.33

KORU Medical Systems, Inc. Provides Revenue Guidance for the Full Year 2023

KORU Medical Systems, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Market Cool On KORU Medical Systems, Inc.'s (NASDAQ:KRMD) Earnings Pushing Shares 28% Lower

KORU Medical Systems, Inc. Announces 510(K) Submission for Freedom60®? Infusion System with Hizentra®? 50 Ml Preilled Syringes

KORU Medical Systems, Inc. Names Andrew LaFrence as Chief Financial Officer

First quarter 2023 earnings: EPS in line with expectations, revenues disappoint

KORU Medical Systems, Inc. Reaffirms Earnings Guidance for the Year 2023

Full year 2022 earnings: EPS exceeds analyst expectations

Price target increased to US$4.83

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

KORU Medical Revised Revenue Guidance for the Full Year of 2022

KORU Medical Systems, Inc. to Report Q3, 2022 Results on Nov 09, 2022

We're Not Very Worried About KORU Medical Systems' (NASDAQ:KRMD) Cash Burn Rate

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

KORU Medical Systems, Inc. Revises Earnings Guidance for the Full Year 2022

KORU Medical Systems, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Repro Med Systems, Inc. Announces Chief Financial Officer Changes

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

KORU Medical Systems Revises Earnings Guidance for the Year 2022

Price target decreased to US$4.67

Repro Med Systems, Inc. to Report Q1, 2022 Results on May 04, 2022

Repro Med Systems, Inc. Appoints Brian Case as Chief Technology Officer

Consensus forecasts updated

Repro Med Systems, Inc. Provides Revenue Guidance for the Fiscal Year 2022

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Repro Med Systems, Inc. to Report Q4, 2021 Results on Mar 02, 2022